Related references
Note: Only part of the references are listed.Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy The Treating to New Targets (TNT) Study
Samia Mora et al.
CIRCULATION (2012)
Approach to the Patient with Extremely Low HDL-Cholesterol
Daniel J. Rader et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals
Christiane L. Haase et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Niacin and Statin Combination Therapy for Atherosclerosis Regression and Prevention of Cardiovascular Disease Events Reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Trial With Previous Surrogate Endpoint Trials
Erin D. Michos et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
On-Treatment Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Samia Mora et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events MESA (Multi-Ethnic Study of Atherosclerosis)
Rachel H. Mackey et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
Aneta Otocka-Kmiecik et al.
PROGRESS IN LIPID RESEARCH (2012)
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH)
B. Gregory Brown et al.
AMERICAN HEART JOURNAL (2011)
Isolated Low Levels of High-Density Lipoprotein Cholesterol Are Associated With an Increased Risk of Coronary Heart Disease An Individual Participant Data Meta-Analysis of 23 Studies in the Asia-Pacific Region
Rachel R. Huxley et al.
CIRCULATION (2011)
HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events
Robert S. Rosenson et al.
CLINICAL CHEMISTRY (2011)
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M. John Chapman et al.
EUROPEAN HEART JOURNAL (2011)
High-Density Lipoprotein Cholesterol as the Holy Grail
Christopher P. Cannon
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms
Mohamad Navab et al.
NATURE REVIEWS CARDIOLOGY (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Meta-analysis: Statin Therapy Does Not Alter the Association Between Low Levels of High-Density Lipoprotein Cholesterol and Increased Cardiovascular Risk
Haseeb Jafri et al.
ANNALS OF INTERNAL MEDICINE (2010)
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
M. John Chapman et al.
EUROPEAN HEART JOURNAL (2010)
Genetic causes of high and low serum HDL-cholesterol
Daphna Weissglas-Volkov et al.
JOURNAL OF LIPID RESEARCH (2010)
The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?
Menno Vergeer et al.
JOURNAL OF LIPID RESEARCH (2010)
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration
Todd C. Villines et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial
Paul M. Ridker et al.
LANCET (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Lipid levels-in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines
Amit Sachdeva et al.
AMERICAN HEART JOURNAL (2009)
High-Density Lipoprotein Particle Size and Concentration and Coronary Risk
Karim El Harchaoui et al.
ANNALS OF INTERNAL MEDICINE (2009)
Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community
Ramachandran S. Vasan et al.
CIRCULATION (2009)
HDL as a Biomarker, Potential Therapeutic Target, and Therapy
Mohamad Navab et al.
DIABETES (2009)
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
The Emerging Risk Factors Collaboration*
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Hepatic Lipase, Genetically Elevated High-Density Lipoprotein, and Risk of Ischemic Cardiovascular Disease
Trine Holm Johannsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and apoB-containing lipoproteins
Stefania Lamon-Fava et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Combined statin and niacin therapy remodels the high-density lipoprotein proteome
Pattie S. Green et al.
CIRCULATION (2008)
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk
Alexander Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for cardiovascular risk - The IDEAL and EPIC-Norfolk studies
Wim A. van der Steeg et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
LANCET (2008)
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study
Matthew J. McQueen et al.
LANCET (2008)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol
Alawi A. Alsheikh-Ali et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Philip Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
High-density lipoprotein as a therapeutic target - A systematic review
Inder M. Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Long-term ethanol consumption impairs reverse cholesterol transport function of high-density lipoproteins by depleting high-density lipoprotein sphingomyelin both in rats and in humans
Philippe Marmillot et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
Effects of lifestyle interventions on high-density lipoprotein cholesterol levels
Michael A. Roussell et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2007)
Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)
PL Canner et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction - The IDEAL study: A randomized controlled trial
TR Pedersen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Clinical practice: Low HDL cholesterol levels
MD Ashen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events
EJ Whitney et al.
ANNALS OF INTERNAL MEDICINE (2005)
Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2 - A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
AJ Taylor et al.
CIRCULATION (2004)
Apolipoprotein A-IMilano:: current perspectives
G Chiesa et al.
CURRENT OPINION IN LIPIDOLOGY (2003)
Antiatherothrombotic effects of nicotinic acid
RS Rosenson
ATHEROSCLEROSIS (2003)
Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS)
MG Shlipak et al.
AMERICAN HEART JOURNAL (2003)
Share Paper
